Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bolt Biotherapeutics (BOLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: BOLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $33.67
1 Year Target Price $33.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.55% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.94M USD | Price to earnings Ratio - | 1Y Target Price 33.67 |
Price to earnings Ratio - | 1Y Target Price 33.67 | ||
Volume (30-day avg) 4 | Beta 0.89 | 52 Weeks Range 4.59 - 14.36 | Updated Date 09/14/2025 |
52 Weeks Range 4.59 - 14.36 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -26.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -510.53% |
Management Effectiveness
Return on Assets (TTM) -33.45% | Return on Equity (TTM) -81.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -645983 | Price to Sales(TTM) 2.39 |
Enterprise Value -645983 | Price to Sales(TTM) 2.39 | ||
Enterprise Value to Revenue 64.2 | Enterprise Value to EBITDA 0.93 | Shares Outstanding 1919440 | Shares Floating 1440656 |
Shares Outstanding 1919440 | Shares Floating 1440656 | ||
Percent Insiders 2.26 | Percent Institutions 44.61 |
Upturn AI SWOT
Bolt Biotherapeutics
Company Overview
History and Background
Bolt Biotherapeutics, founded in 2015, is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness the power of the innate immune system to treat cancer. It went public in February 2021. The company's evolution has centered around developing its Boltbodyu2122 ISAC platform.
Core Business Areas
- Immuno-Stimulating Antibody Conjugates (ISACs): Bolt's core technology is ISACs, designed to redirect myeloid cells to tumors. These conjugates combine antibodies that target tumor-associated antigens with a TLR7/8 agonist, stimulating an immune response within the tumor microenvironment.
Leadership and Structure
Dr. Randall C. Schatzman is the President and CEO. The company has a board of directors and various management teams overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- BDT-6001: BDT-6001 is an ISAC targeting carcinoembryonic antigen (CEA), currently in clinical trials for advanced solid tumors. No market share or revenue is currently generated as it's in clinical development. Competitors include companies developing CEA-targeting therapies and immunotherapies for solid tumors (e.g., Amgen (AMGN), Roche (ROG.SW)).
- BDT-2000: BDT-2000, another ISAC, is designed to target HER2-expressing tumors and is also in early clinical trials. No market share or revenue yet. Competitors include companies developing HER2-targeted therapies (e.g., Genentech/Roche (ROG.SW), AstraZeneca (AZN)).
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically in the immuno-oncology space, is highly competitive and rapidly evolving. It focuses on developing novel therapies to treat cancer by harnessing the immune system.
Positioning
Bolt Biotherapeutics is positioned as an innovator in the ISAC field. Their technology aims to provide a more targeted and effective approach to cancer immunotherapy compared to traditional methods. Their ISAC platform seeks to create an environment that promotes greater efficiency and efficacy of immune targeting of tumors.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is substantial, projected to reach hundreds of billions of dollars. Bolt Biotherapeutics aims to capture a portion of this market by developing effective ISAC therapies for specific tumor types. Market size expected to be 171.9 billion USD by 2030.
Upturn SWOT Analysis
Strengths
- Novel ISAC technology platform
- Targeted approach to cancer immunotherapy
- Potential for strong efficacy with manageable toxicity
- Experienced management team
Weaknesses
- Early stage clinical development
- Limited clinical data
- Dependence on successful clinical trials
- High cash burn rate
- Stock dilution
Opportunities
- Expansion of ISAC platform to other tumor types
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Development of companion diagnostics
Threats
- Clinical trial failures
- Competition from established immunotherapy companies
- Regulatory hurdles
- Patent challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- Amgen (AMGN)
- Roche (ROG.SW)
- AstraZeneca (AZN)
Competitive Landscape
Bolt Biotherapeutics is competing with larger, more established pharmaceutical companies. Its competitive advantage lies in its novel ISAC platform, but it faces challenges in securing funding and navigating regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement in clinical trials and expansion of its pipeline.
Future Projections: Future growth depends on the successful completion of clinical trials and potential partnerships. Analyst estimates vary widely, reflecting the uncertainty of drug development.
Recent Initiatives: Recent initiatives include advancing BDT-6001 and BDT-2000 through clinical trials and exploring new ISAC targets.
Summary
Bolt Biotherapeutics is a high-risk, high-reward clinical-stage company. Its innovative ISAC technology holds promise, but it faces significant challenges in clinical development and competition. Financial stability depends on securing funding and achieving clinical milestones. The company is well-positioned in the emerging immuno-oncology market if trials are successful. They must minimize cash burn until then.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bolt Biotherapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bolt Biotherapeutics
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO, CFO, President, Secretary & Director Mr. William P. Quinn | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.boltbio.com |
Full time employees 52 | Website https://www.boltbio.com | ||
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.